Phase 1/2, open-label, randomized study of the safety, efficacy and pharmacokinetics of Letrozole plus PD 0332991 (oral CDK 4/6 inhibitor) and Letrozole single agent for the first-line treatment of ER Positive, HER2 negative ADVANCED Breast

Project: Research

Participants

  • Daniel Rea (Principal Investigator)
  • (Co-Investigator)
Short titlePhase 1/2, open-label, randomized study of the safety, efficacy and pharmacokinetics of Letrozole plus PD 0332991 (oral CDK 4/6 inhibitor) and Letrozole single agent for the first-line treatment of ER Positive, HER2 negative ADVANCED Breast
StatusFinished
Effective start/end date1/01/1231/12/14